Reproductive safety of bisphosphonates in women of childbearing age
10.3760/cma.j.issn.1000-6699.2019.05.018
- VernacularTitle:二膦酸盐应用于育龄期女性的生殖安全性
- Author:
Wen CHEN
1
;
Qin WANG
;
Jing LI
;
Chunyan LU
;
Decai CHEN
Author Information
1. 四川大学华西医院内分泌与代谢病科
- Keywords:
Bisphosphonate;
Women of childbearing age;
Reproductive safety;
Breastfeeding;
Pregnancy;
Fetus
- From:
Chinese Journal of Endocrinology and Metabolism
2019;35(5):441-446
- CountryChina
- Language:Chinese
-
Abstract:
Bisphosphonates ( BPs) are bone resorption inhibitors, which are increasingly used in the treatment of bone metabolic diseases in women of childbearing age. It is unclear whether the use of BPs in women of childbearing age will affect the health of their offspring. This article retrieved 66 reports in the past 40 years by searching on the databases of Pubmed, Embase, Ovid, Medline and so on. A number of reports found that BPs may be responsible for shortening gestational age, increasing spontaneous abortion, and decreasing neonatal birth weight. Three women's offsprings were found to have abnormal blood calcium after birth. Cases of skeletal malformations include two bilateral talipes equinus, one Apert's syndrome and one rickets. However, there have been many reports of no reproductive abnormalities or abnormal blood calcium level. Occasionally, children breast-fed by women who had received BPs have had a transient hypocalcemia. There is currently insufficient evidence to confirm that BPs can cause significant reproductive malformations during pregnancy or pre-pregnancy. However, due to the long-term presence of BPs in the bones, women of childbearing age who have a need for pregnancy should choose to use these drugs with caution.
